Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
NCT ID: NCT07323329
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
165 participants
INTERVENTIONAL
2025-10-10
2026-11-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is:
Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dehydroepiandrosterone (DHEA)Supplementation Pre-IVF(In Vitro Fertilization) Cycles
NCT02866253
DHEA Versus Placebo in Women With Poor Ovarian Response
NCT02561793
Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response?
NCT02151006
Use of Dehydroepiandrosterone (DHEA) in Women With Normal and Poor Ovarian Reserve Undergoing IVF
NCT01915186
The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders
NCT02357472
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Somatropin group
Somatropin (4IU for 1 month) 1 S.C injection every 3 days for at least 1 month plus, folic acid 400mcg/day
Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.
Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.
dehydroepiandrosterone
dehydroepiandrosterone 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
DHEA plus folic acid 400mcg per day
Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
Standard care
Patients will receive standard care will receive folic acid 400 mcg per day
control group
Patients will receive folic acid 400 mcg per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.
Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.
DHEA plus folic acid 400mcg per day
Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day
control group
Patients will receive folic acid 400 mcg per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Advanced maternal age (\>40 years) or any other risk factor for Poor Ovarian Response (POR).
2. ≤3 oocytes with a conventional stimulation protocol).
3. An abnormal ovarian reserve test \[i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml\].
Exclusion Criteria
2. Any pelvic pathology such as hydrosalpinx, uterine anomaly.
3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beni-Suef University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasnaa Osama
Lecturer of Clinical Pharmacy, Beni-Suef University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beni-Suef University Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000 Oct;15(10):2129-32. doi: 10.1093/humrep/15.10.2129.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMBSUREC/01092024/Ragab
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.